A pharmacoeconomic evaluation of the pharmacotherapeutic options for painful diabetic neuropathy

References

• Khdour MR. Treatment of diabetic peripheral neuropathy: a review. J Pharm Pharmacol. 2020;72(7):863–872.
   PubMed Web of Science ®Google Scholar
• Tolle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications. 2006;20(1):26–33.
   PubMed Web of Science ®Google Scholar
• Timar B, Timar R, Gaita L, et al. The impact of diabetic neuropathy on balance and on the risk of falls in patients with Type 2 diabetes mellitus: a cross-sectional study. PLoS One. 2016;11(4):e0154654.
   PubMed Web of Science ®Google Scholar
• Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495–505.
   PubMed Web of Science ®Google Scholar
• Kim JH, Jung MH, Lee JM, et al. Diabetic peripheral neuropathy is highly associated with nontraumatic fractures in Korean patients with type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2012;77(1):51–55.
   PubMed Web of Science ®Google Scholar
• Sadosky A, Mardekian J, Parsons B, et al. Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complications. 2015;29(2):212–217.
   PubMed Web of Science ®Google Scholar
• Ebata-Kogure N, Nozawa K, Murakami A, et al. Clinical and economic burdens experienced by patients with painful diabetic peripheral neuropathy: an observational study using a Japanese claims database. PLoS One. 2017;12(10):e0187250.
   PubMed Web of Science ®Google Scholar
• McDermott AM, Toelle TR, Rowbotham DJ, et al. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain. 2006;10(2):127–135.
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the american diabetes association. Diabetes Care. 2017;40(1):136–154.
   PubMed Web of Science ®Google Scholar
• Branch Group of Neurological Complications CDS. Expert consensus on diagnosis and treatment of diabetic neuropathy (2021 edition). Chinese Journal of Diabetes Mellitus. 2021;13(6):540–557.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Neuropathic pain in adults: pharmacological management in non-specialist settings. London: National Institute for Health and Care Excellence (UK); 2020 September 22.
   Google Scholar
• Dworkin RH, Panarites CJ, Armstrong EP, et al. Healthcare utilization in people with postherpetic neuralgia and painful diabetic peripheral neuropathy. J Am Geriatr Soc. 2011;59(5):827–836.
   PubMed Web of Science ®Google Scholar
• Kiyani M, Yang Z, Charalambous LT, et al. Painful diabetic peripheral neuropathy: health care costs and complications from 2010 to 2015. Neurol Clin Pract. 2020;10(1):47–57.
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):b2535.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250.
   PubMed Web of Science ®Google Scholar
• Carlos F, Ramírez-Gámez J, Dueñas H, et al. Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico. J Med Econ. 2012;15(2):233–244.
   PubMedGoogle Scholar
• Sankar V, Oommen AE, Thomas A, et al. Efficacy, safety and cost effectiveness of amitriptyline and pregabalin in patients with diabetic peripheral neuropathy. Indian J Pharm Sci. 2017;79(4):646–650.
   Web of Science ®Google Scholar
• Roy MK, Kuriakose AS, Varma SK, et al. A study on comparative efficacy and cost effectiveness of pregabalin and duloxetine used in diabetic neuropathic pain. Diabetes Metab Syndr. 2016;11(1):31–35.
   PubMed Web of Science ®Google Scholar
• Carlos F, Espejel L, Novick D, et al. Duloxetine for the treatment of painful diabetic peripheral neuropathy in Venezuela: economic evaluation. Medwave. 2015;15(8):e6265.
   PubMedGoogle Scholar
• Athanasakis K, Petrakis I, Karampli E, et al. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting. BMC Neurol. 2013;13(1):56.
   PubMedGoogle Scholar
• Bellows BK, Dahal A, Jiao T, et al. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy. J Pain Palliat Care Pharmacother. 2012;26(2):153–164.
   PubMedGoogle Scholar
• Rodriguez MJ, Diaz S, Vera-Llonch M, et al. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin. 2007;23(10):2585–2596.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain. 2006;7(6):399–407.
   PubMed Web of Science ®Google Scholar
• Tarride JE, Gordon A, Vera-Llonch M, et al. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther. 2006;28(11):1922–1934.
   PubMed Web of Science ®Google Scholar
• O’Connor AB, Noyes K, Holloway RG. A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics. 2008;26(12):1045–1064.
   PubMed Web of Science ®Google Scholar
• Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. J Pain. 2006;7(2):119–128.
   PubMed Web of Science ®Google Scholar
• Gray E, Ye X, Wang YF, et al. Cost-effectiveness of mirogabalin for the treatment of diabetic peripheral neuropathic pain in Taiwan. Value Health Reg Issues. 2021;24:148–156.
   PubMedGoogle Scholar
• Bellows BK, Nelson RE, Oderda GM, et al. Long-term cost-effectiveness of initiating treatment for painful diabetic neuropathy with pregabalin, duloxetine, gabapentin, or desipramine. Pain. 2016;157(1):203–213.
   PubMed Web of Science ®Google Scholar
• Gordon J, Lister S, Prettyjohns M, et al. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain. J Med Econ. 2012;15(2):207–218.
   PubMedGoogle Scholar
• de Salas-cansado M, Perez C, Saldana MT, et al. A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain. Pain Med. 2012;13(5):699–710.
   PubMed Web of Science ®Google Scholar
• Annemans L, Caekelbergh K, Morlion B, et al. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain. Acta Clin Belg. 2008;63(3):170–178.
   PubMed Web of Science ®Google Scholar
• Beard SM, McCrink L, Le TK, et al. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Curr Med Res Opin. 2008;24(2):385–399.
   PubMed Web of Science ®Google Scholar
• de Salas-cansado M, Perez C, Saldana MT, et al., An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings. Prim Care Diabetes. 6(4): 303–312. 2012.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Mirogabalin: first global approval. Drugs. 2019;79(4):463–468.
   PubMed Web of Science ®Google Scholar
• Baba M, Matsui N, Kuroha M, et al. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 2019;10(5):1299–1306.
   PubMed Web of Science ®Google Scholar
• Rendell MS. The time to develop treatments for diabetic neuropathy. Expert Opin Investig Drugs. 2021;30(2):119–130.
   PubMed Web of Science ®Google Scholar
• Alleman CJ, Westerhout KY, Hensen M, et al., Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: a review of the literature. Diabetes Res Clin Pract. 109(2): 215–225. 2015.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Ricci JA, Chee E, et al. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. J Occup Environ Med. 2007;49(6):672–679.
   PubMed Web of Science ®Google Scholar
• Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–862.
   PubMed Web of Science ®Google Scholar
• Kahm K, Laxy M, Schneider U, et al. Exploring different strategies of assessing the economic impact of multiple diabetes-associated complications and their interactions: a large claims-based study in Germany. Pharmacoeconomics. 2019;37(1):63–74.
   PubMed Web of Science ®Google Scholar
• Andersson E, Persson S, Hallén N, et al., Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden. Diabetologia. 63(12): 2582–2594. 2020.
   PubMed Web of Science ®Google Scholar
• Zaheer A, Zaheer F, Saeed H, et al. A review of alternative treatment options in diabetic polyneuropathy. Cureus. 2021;13(4):e14600.
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Sloan G. Diabetic polyneuropathy - Advances in diagnosis and intervention strategies. Eur Endocrinol. 2020;16(1):15–20.
   PubMedGoogle Scholar
• Ziegler D, Papanas N, Schnell O, et al. Current concepts in the management of diabetic polyneuropathy. J Diabetes Investig. 2021;12(4):464–475.
   PubMed Web of Science ®Google Scholar
• Bates D, Schultheis BC, Hanes MC, et al. A comprehensive algorithm for management of neuropathic pain. Pain Med. 2019;20(Suppl 1):S2–S12.
   PubMedGoogle Scholar
• Pafili K, and Papanas N. Considerations for single- versus multiple-drug pharmacotherapy in the management of painful diabetic neuropathy. Expert Opin Pharmacother. 2021;22(16):2267–2280.
   PubMed Web of Science ®Google Scholar